Drugs that aggravate the course of COVID-19: really?.
Revue Medicale Suisse
; 16(691):852-854, 2020.
Artículo
en Francés
| EMBASE | ID: covidwho-20242159
ABSTRACT
The safety of NSAIDs, corticosteroids and renin-angiotensin inhibitors in COVID-19 is challenged. NSAIDs may interfere with the defense process against viral infection and are best avoided. Systemic corticosteroids have not shown benefit in viral infection, including other coronavirus;thus they should be avoided, unless prescribed for another indication. The benefit-risk ratio is however clearly in favor of continuing inhaled corticosteroids in patients with asthma or COPD. ACE inhibitors and sartans upregulate the expression of angiotensin-converting enzyme 2 (ACE2), the pulmonary receptor for SARS-CoV-2. Any possible clinical impact of these treatments on COVID-19 infection remains to be clarified;in the meantime, they should be continued.Copyright © 2020 Editions Medecine et Hygiene. All rights reserved.
article; asthma; chronic obstructive lung disease; coronavirus disease 2019/dt [Drug Therapy]; drug safety; human; risk assessment; upregulation; angiotensin converting enzyme 2/ec [Endogenous Compound]; corticosteroid/dt [Drug Therapy]; corticosteroid/ih [Inhalational Drug Administration]; nonsteroid antiinflammatory agent/dt [Drug Therapy]; sartan derivative/dt [Drug Therapy]
Texto completo:
Disponible
Colección:
Bases de datos de organismos internacionales
Base de datos:
EMBASE
Tipo de estudio:
Estudio pronóstico
Idioma:
Francés
Revista:
Revue Medicale Suisse
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS